 | Up a level |
2015
Gaidzik, V., I, Weber, D., Paschka, P., Krieger, S., Kaumanns, A., Kroenke, J., Kapp-Schwoerer, S., Koehne, C-H, Horst, H-A, Schmidt-Wolf, I. G. H., Held, G., Kuendgen, A., Ringhoffer, M., Goetze, K., Kindler, T., Fiedler, W., Wattad, M., Corbacioglu, A., Bullinger, L., Schlegelberger, B., Thol, F., Heuser, M., Ganser, A., Schlenk, R. F., Doehner, H. and Doehner, K. (2015). DNMT3A mutations (DNMT3Amut) in acute myeloid leukemia (AML): monitoring of minimal residual disease (MRD). A study of the AML Study Group (AMLSG). Oncol. Res. Treat., 38. S. 7 - 8. BASEL: KARGER. ISSN 2296-5262
Mai, E. K., Benner, A., Bertsch, U., Schmidt-Wolf, I. G. H., Haenel, A., Kunzmann, V, Naumann, R., Neben, K., Egerer, G., Hillengass, J., Neubauer, A., Peyn, A., Ko, Y-D, Peter, N., Salwender, H. J., Scheid, C. and Goldschmidt, H. (2015). Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in newly-diagnosed multiple myeloma: final results from the GMMG-HD2 trial. Oncol. Res. Treat., 38. S. 9 - 11. BASEL: KARGER. ISSN 2296-5262
Mai, E. K., Bertsch, U., Duerig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W, Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H. and Goldschmidt, H. (2015). Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia, 29 (8). S. 1721 - 1730. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
2014
Mai, E. K., Bertsch, U., Duerig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W, Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H. and Goldschmidt, H. (2014). Bortezomib/cyclophosphamide/dexamethasone (VCD) is equally effective and has a favorable toxicity profile compared to bortezomib/doxorubicin/dexamethasone (PAd) as induction therapy in newly diagnosed, transplant-eligible myeloma patients: Results from the multicenter, phase III clinical trial GMMG-MM5. Oncol. Res. Treat., 37. S. 150 - 152. BASEL: KARGER. ISSN 2296-5262
Schmidt-Wolf, I. G. H., Straka, C., Scheid, C., Einsele, H., Goldschmidt, H. and Engelhardt, M. (2014). State of the art treatment of progressive or refractory multiple myeloma. Dtsch. Med. Wochenschr., 139 (41). S. 2091 - 2096. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-4413
2012
Linnebank, M., Moskau, S., Kowoll, A., Semmler, A., Bangard, C., Vogt-Schaden, M., Egerer, G., Schackert, G., Reichmann, H., Schmidt-Wolf, I. G. H., Pels, H. and Schlegel, U. (2012). Association of transcobalamin c. 776C > G with overall survival in patients with primary central nervous system lymphoma. Br. J. Cancer, 107 (11). S. 1840 - 1844. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827